Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion
Status:
Completed
Trial end date:
2000-03-01
Target enrollment:
Participant gender:
Summary
3-Hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) decrease apolipoprotein
B-100-containing lipoproteins by increasing their fractional catabolic rates through
low-density lipoproteins (LDL) receptor-mediated uptake. Their influence on hepatic secretion
of these lipoproteins is controversial. The current study investigates whether simvastatin
influences lipoprotein secretion.